Abstract
The most common destination for breast cancer metastases is bone. If bone metastases are detected, treatment algorithms should include the continuation of cytoreductive therapy with the addition of treatment to counter skeletal-related events, including bone pain. The range of current treatment options includes bisphosphonates, surgical intervention to improve structural integrity and palliative focal radiotherapy. This article focuses on the role of bisphosphonate therapy in metastatic breast cancer. Bisphosphonate therapy significantly reduces the impact of skeletal-related events, reduces bone pain and increases patient quality of life. Our current understanding is that bisphosphonates may also disrupt the metastatic process and reduce the development of bone lesions. Ultimately, this may lead to further expansion of bisphosphonate-based therapy in the future.
| Originalsprache | Englisch |
|---|---|
| Seiten (von - bis) | 149-163 |
| Seitenumfang | 15 |
| Fachzeitschrift | Women's Health |
| Jahrgang | 5 |
| Ausgabenummer | 2 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - März 2009 |
| Extern publiziert | Ja |
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gute Gesundheit und Wohlergehen
Fingerprint
Untersuchen Sie die Forschungsthemen von „Treatment options for breast cancer and bone metastases“. Zusammen bilden sie einen einzigartigen Fingerprint.Dieses zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver